Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rose 2.2% on Thursday . The stock traded as high as $89.64 and last traded at $89.03, with a volume of 1,495,965 shares traded. The stock had previously closed at $87.12.

BMRN has been the topic of several recent research reports. William Blair reissued a “buy” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, March 22nd. Cowen and Company reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Sunday, April 17th. Jefferies Group reaffirmed a “buy” rating and issued a $116.00 price target (down previously from $120.00) on shares of BioMarin Pharmaceutical in a research note on Friday, April 8th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, April 20th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Saturday, March 19th. Three investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $122.96.

The stock has a 50 day moving average of $84.12 and a 200 day moving average of $84.06. The firm’s market capitalization is $14.45 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, April 28th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.32. During the same quarter in the previous year, the firm earned ($0.43) EPS. The business earned $236.70 million during the quarter, compared to analysts’ expectations of $240.21 million. BioMarin Pharmaceutical’s quarterly revenue was up 16.7% on a year-over-year basis. Analysts predict that BioMarin Pharmaceutical Inc. will post ($2.84) EPS for the current fiscal year.

In related news, CEO Jean Jacques Bienaime sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, May 5th. The stock was sold at an average price of $80.15, for a total value of $4,007,500.00. Following the transaction, the chief executive officer now owns 390,156 shares in the company, valued at $31,271,003.40. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Daniel K. Spiegelman sold 20,841 shares of the company’s stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $89.88, for a total value of $1,873,189.08. Following the completion of the transaction, the chief financial officer now owns 71,235 shares in the company, valued at approximately $6,402,601.80. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in BioMarin Pharmaceutical by 3.3% in the fourth quarter. Vanguard Group Inc. now owns 11,195,877 shares of the company’s stock valued at $1,172,880,000 after buying an additional 355,727 shares during the last quarter. CAM Group Holding A S increased its position in BioMarin Pharmaceutical by 73.6% in the fourth quarter. CAM Group Holding A S now owns 127,575 shares of the company’s stock valued at $13,365,000 after buying an additional 54,100 shares during the last quarter. GAM Holding AG increased its position in BioMarin Pharmaceutical by 60.4% in the fourth quarter. GAM Holding AG now owns 89,329 shares of the company’s stock valued at $9,358,000 after buying an additional 33,651 shares during the last quarter. Jennison Associates increased its position in BioMarin Pharmaceutical by 25.0% in the third quarter. Jennison Associates now owns 150,000 shares of the company’s stock valued at $15,798,000 after buying an additional 30,000 shares during the last quarter. Finally, ING Groep increased its position in BioMarin Pharmaceutical by 524.1% in the third quarter. ING Groep now owns 15,460 shares of the company’s stock valued at $1,628,000 after buying an additional 12,983 shares during the last quarter.

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.